The head of SHINE Technologies’ therapeutics division says the company is moving from research and development into the commercial stage for a precision cancer treatment product.
The Janesville company recently submitted its “drug master file” to the FDA, which includes information on facilities, procedures and other details for production of non-carrier-added lutetium-177 chloride. This ...
Please log in to access subscriber content.
If you don't have a subscription, click
here for a WisPolitics free trial and to view the different subscription options.
